Centene Corp. (CNC) Stock Analysis

62.0/100
Hold Not Halal Healthcare
Price $71.27
Market Cap $35.28B
52-Week Change +97.48%

Is CNC a good investment?

Centene Corp. (CNC) has a Plutrex AI rating of 62.0/100 as of November 11, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: 5-Year Forward EPS Growth of 46.94% is 179% above the industry average of 16.82%, driving a PEG ratio of 0.51 vs industry 1.58 — if even partially realized, this represents significant undervaluation on a growth-adjusted basis; $23.6B cash fortress and $3.96B FCF (~$10/share) provide exceptional downside protection. Main concern: Analyst consensus target SLASHED from $79.25 to $73.50 (-7.3% in 14 days) — with stock at $70.19, this leaves only 4.7% upside to the new consensus, fundamentally breaking the prior report's 1.92x risk/reward thesis; a 7-point target cut in two weeks signals sell-side conviction loss that dominates all other near-term considerations.

Investment Summary

Centene (CNC) at $70.19 is a managed care company with a deeply mixed investment profile. The stock carries razor-thin net margins of 0.7%, ROE of 6.77% (vs industry 13.58%), and near-stagnant revenue growth of 0.2% (vs industry 4.24%). The critical anchor: the analyst consensus target has DROPPED materially from $79.25 (prior report) to $73.50 — a 7.3% downward revision that transforms the risk/reward math. At $70.19, this implies only 4.7% upside to the new consensus target versus meaningful downside risk. The bull case rests entirely on the 46.94% five-year EPS growth projection (179% above industry average of 16.82%) and a PEG of 0.51 (67.7% below peers), but near-term evidence contradicts this optimism: next-year EPS growth is only 5.03% vs industry 18.57%. News sentiment is positive at 81.8/100, but specific developments (DOJ whistleblower lawsuit intervention, election policy uncertainty) carry headline risk. The stock is a Weak Hold — the analyst target cut is the dominant new development that overrides the otherwise constructive news flow.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
72/100
Growth Potential
60/100
Valuation
58/100
Profitability
18/100
Debt Management
70/100
Analyst Sentiment
55/100
Technical Momentum
65/100
Insider Confidence
50/100
News Sentiment
72/100

Fundamental Analysis

CNC's fundamentals reflect managed care's inherent structural constraints. Net margin 0.7% (vs industry 2.33%) and operating margin 0.74% (vs industry 3.31%) leave virtually zero cushion against medical cost inflation. ROE 6.77% is 50% below the industry average of 13.58%, indicating poor capital efficiency. Revenue growth of 0.2% vs industry 4.24% is essentially flat — a 95% underperformance vs peers. The P/E of 24.05x sits 30.3% above the industry average of 18.45x, an unjustifiable premium given inferior near-term metrics. The PEG of 0.51 vs industry 1.58 is mathematically compelling but critically dependent on 46.94% five-year EPS growth materializing despite near-zero revenue growth. Price-to-Book of 1.56x and cash of $23.6 billion ($10/share FCF) provide downside cushioning. D/E of 0.70 vs industry 0.729 is marginally better than peers. The core tension: a 30.3% PE premium to peers is unsustainable if revenue growth stays at 0.2% and next-year EPS growth delivers only 5.03%.

News Sentiment

Centene Corp is navigating a complex political and operational landscape as investors weigh what Washington's shifting power balance means for the managed healthcare giant. Following midterm results that sent hospital stocks surging — a signal that markets expect favorable healthcare policy — Centene is in focus as a beneficiary of a stable or expanding Medicaid and ACA environment. But not all the news is clean. The U.S. Department of Justice has intervened in a health insurance whistleblower lawsuit involving a healthcare company, creating a headline that managed care investors cannot ignore (headline #4). While Centene has not been specifically named as the target, DOJ intervention in whistleblower cases signals potential regulatory scrutiny that could affect the broader managed care space — including Centene's government-sponsored program business. On the positive side, Centene's subsidiary Meridian Health Plan of Illinois announced a nearly $1.2M partnership with March of Dimes (headline #2) — a move that aligns with the company's core Medicaid population and maternal health mission, potentially improving outcomes and reducing costly complications. Meanwhile, one analyst took a bullish view, noting 'Three Key Takeaways for Long-Term Investors' that focus on CNC's multi-year earnings recovery story. The stock hit a fresh high recently (headline #3), raising the question of whether there's room to run — especially as the consensus analyst target has quietly been trimmed. For everyday investors, the message is: Centene has real long-term promise, but the near-term entry point matters more than ever.

Risk Assessment

PRIMARY RISK: Analyst consensus target declined from $79.25 to $73.50 in 14 days — a $5.75 (-7.3%) cut that is the most material single data point change since the prior report. At current $70.19, this creates a narrow 4.7% upside corridor that makes current prices unattractive for new entry. SECONDARY RISK: DOJ intervention in health insurance whistleblower lawsuit (headline #4) is an open regulatory tail risk with no quantified impact — managed care companies have historically faced material settlements. STRUCTURAL RISK: 0.7% net margin means a 1-point increase in medical cost ratio eliminates all profitability; ACA enrollment already dropped 18% from 25.2M to 20.5M. MITIGATION: Wait for pullback to $64-67 range (8.8-9.5% below current) which would price the stock at approximately 6.5x FCF — historically inexpensive for large managed care — and restore a 1.35x+ risk/reward to even the reduced $73.50 analyst target.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is CNC a halal stock?

No, Centene Corp. (CNC) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for CNC?

Centene Corp. (CNC) has a Plutrex AI rating of 62.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is CNC a good investment?

According to Plutrex AI, CNC has a Hold rating (62.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in CNC?

US stocks like CNC can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in CNC?

Plutrex AI identifies the main risks for CNC by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about CNC

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open CNC in ElBarake